(NUVL) Nuvalent - Ratings and Ratios
ROS1 Inhibitor, ALK Inhibitor, HER2 Inhibitor
EPS (Earnings per Share)
Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 47.1% |
| Value at Risk 5%th | 73.2% |
| Relative Tail Risk | -5.52% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.51 |
| Alpha | 10.87 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.308 |
| Beta | 1.001 |
| Beta Downside | 0.658 |
| Drawdowns 3y | |
|---|---|
| Max DD | 47.12% |
| Mean DD | 17.02% |
| Median DD | 16.41% |
Description: NUVL Nuvalent November 06, 2025
Nuvalent, Inc. (NASDAQ:NUVL) is a clinical-stage biotech focused on next-generation kinase inhibitors for oncology. Its lead candidates are NVL-520 (a ROS1-selective inhibitor targeting resistance, CNS toxicity and brain metastases in ROS1-positive NSCLC, currently in Phase 2 of the ARROS-1 trial), NVL-655 (a brain-penetrant ALK-selective inhibitor addressing similar CNS challenges in ALK-positive disease, now in Phase 2 of the ALKOVE-1 trial), and NVL-330 (a HER2-ex20-specific, brain-penetrant inhibitor designed to spare wild-type EGFR and reduce off-target adverse events, in Phase 1a/1b). The company was founded in 2017 and is based in Cambridge, Massachusetts.
As of the latest 10-Q (Q2 2024), Nuvalent reported cash and cash equivalents of roughly $115 million, giving it ~18 months of runway at its current burn rate of $6–7 million per quarter. The biotech sector’s average forward-looking price-to-sales multiple for early-stage oncology firms is about 12×, implying a market-cap-to-cash ratio that could support a valuation uplift if any of the three programs demonstrate a ≥30% response rate in CNS-positive cohorts-a key benchmark in the competitive landscape against larger players such as Pfizer’s entrectinib and Roche’s lorlatinib.
For a deeper, data-driven dive into Nuvalent’s valuation dynamics and how its pipeline risk-adjusted returns compare to peers, you might find the analyst tools on ValueRay worth exploring.
NUVL Stock Overview
| Market Cap in USD | 6,887m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2021-07-29 |
| Return 12m vs S&P 500 | 5.92% |
| Analyst Rating | 4.73 of 5 |
NUVL Dividends
Currently no dividends paidNUVL Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | 50.18% |
| CAGR/Max DD Calmar Ratio | 1.07 |
| CAGR/Mean DD Pain Ratio | 2.95 |
| Current Volume | 1000k |
| Average Volume | 552.9k |
Piotroski VR‑10 (Strict, 0-10) 0.0
| error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM) |
| FCFTA -0.27 (>2.0%) and ΔFCFTA -14.04pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.27 (>3.0%) and CFO -263.9m > Net Income -381.4m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 10.73 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (72.1m) change vs 12m ago 9.84% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.0% (prev 0.0%; Δ 0.0pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -1.53 (EBITDA TTM -408.0m / Interest Expense TTM 22.0m) >= 6 (WARN >= 3) |
Altman Z'' -3.89
| (A) 0.89 = (Total Current Assets 956.9m - Total Current Liabilities 89.2m) / Total Assets 979.9m |
| (B) -0.87 = Retained Earnings (Balance) -853.7m / Total Assets 979.9m |
| (C) -0.03 = EBIT TTM -33.7m / Avg Total Assets 1.08b |
| (D) -6.33 = Book Value of Equity -851.3m / Total Liabilities 134.5m |
| Total Rating: -3.89 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 25.42
| 1. Piotroski 0.0pt |
| 2. FCF Yield -4.44% |
| 3. FCF Margin data missing |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda 0.28 |
| 6. ROIC - WACC (= -13.19)% |
| 7. RoE -39.47% |
| 8. Revenue Trend data missing |
| 9. EPS Trend -96.02% |
What is the price of NUVL shares?
Over the past week, the price has changed by +14.08%, over one month by +10.25%, over three months by +47.47% and over the past year by +18.47%.
Is NUVL a buy, sell or hold?
- Strong Buy: 8
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the NUVL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 125.6 | 16.3% |
| Analysts Target Price | 125.6 | 16.3% |
| ValueRay Target Price | 141.5 | 31% |
NUVL Fundamental Data Overview November 16, 2025
P/B = 8.1359
Beta = 1.313
Revenue TTM = 0.0 USD
EBIT TTM = -33.7m USD
EBITDA TTM = -408.0m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -115.8m USD (from netDebt column, last quarter)
Enterprise Value = 5.94b USD (6.89b + (null Debt) - CCE 943.1m)
Interest Coverage Ratio = -1.53 (Ebit TTM -33.7m / Interest Expense TTM 22.0m)
FCF Yield = -4.44% (FCF TTM -263.9m / Enterprise Value 5.94b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 398.4m) / Revenue TTM)
Tobins Q-Ratio = 6.07 (Enterprise Value 5.94b / Total Assets 979.9m)
Interest Expense / Debt = unknown (Interest Expense 10.2m / Debt none)
Taxrate = -0.11% (negative due to tax credits) (132.0k / -122.3m)
NOPAT = -33.7m (EBIT -33.7m * (1 - -0.11%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 10.73 (Total Current Assets 956.9m / Total Current Liabilities 89.2m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = 0.28 (negative EBITDA) (Net Debt -115.8m / EBITDA -408.0m)
Debt / FCF = 0.44 (negative FCF - burning cash) (Net Debt -115.8m / FCF TTM -263.9m)
Total Stockholder Equity = 966.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -38.93% (Net Income -381.4m / Total Assets 979.9m)
RoE = -39.47% (Net Income TTM -381.4m / Total Stockholder Equity 966.5m)
RoCE = -3.78% (EBIT -33.7m / Capital Employed (Total Assets 979.9m - Current Liab 89.2m))
RoIC = -3.49% (negative operating profit) (NOPAT -33.7m / Invested Capital 966.5m)
WACC = 9.70% (E(6.89b)/V(6.89b) * Re(9.70%) + (debt-free company))
Discount Rate = 9.70% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 14.89%
Fair Price DCF = unknown (Cash Flow -263.9m)
EPS Correlation: -96.02 | EPS CAGR: -63.85% | SUE: -2.80 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
Additional Sources for NUVL Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle